Intellia Therapeutics (NTLA) announced the FDA has removed the clinical hold on the Investigational New Drug application for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran for patients with transthyretin amyloidosis with cardiomyopathy. The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed by the FDA on October 29, 2025, following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in MAGNITUDE that met the trials protocol-defined pausing criteria.
Intellia CEO John Leonard said: "With the resolution in January of the clinical hold on our MAGNITUDE-2 Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials."
In pre-market trading on NasdaqGM, Intellia shares are up 3.56 percent to $14.27.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.